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Abstract
Interleukin (IL)-13 is produced by T helper 2 (Th2)-type cells and inhibits the production of proinflammatory cytokines by activated
monocytes, while IL-18 is a pleiotropic cytokine that induces interferon-Q and plays an important role in the development of Th1-type cells.
Role of the shift from a Th1-type response to Th2-type has been suggested in the pathogenesis of dengue hemorrhagic fever (DHF). This
study was undertaken to investigate the possible protective/pathogenic role of IL-13 and IL-18 in patients with DHF. Sera were collected
from a total of 84 patients with various grades of dengue illness and 21 normal healthy controls and tested for IL-13 and IL-18 levels using
commercial enzyme-linked immunosorbent assay kits. The results showed that very low levels of IL-13 (4 þ 3 pg ml31) and IL-18 (15 þ 4 pg
ml31) were detected in the sera of healthy controls. In dengue patients, the levels of IL-13 and IL-18 were the highest in the patients with
DHF grade IV (205 þ 103 pg ml31 and 366 þ 155 pg ml31, respectively) and the lowest in patients with dengue fever (22 þ 12 pg ml31 and
76 þ 50 pg ml31, respectively). Both the cytokines appeared (IL-13 = 20 þ 11 pg ml31 and IL-18 = 70 þ 45 pg ml31) during the first 4 days of
illness and reached peak levels (IL-13 = 204 þ 96 pg ml31 and IL-18 = 360 þ 148 pg ml31) by day 9 onwards. The presence of high levels of
IL-13 and IL-18 during severe illness and late phases of the disease suggests that both of these cytokines may contribute to the shift from a
Th1- to Th2-type response and thus to the pathogenesis of DHF. ß 2001 Federation of European Microbiological Societies. Published by
Elsevier Science B.V. All rights reserved.
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1. Introduction
Interleukin (IL)-13 is produced by T helper 2 (Th2)-type
cells and inhibits the production of proin£ammatory cyto-
kines by activated monocytes, induces B cell proliferation
and di¡erentiation including IgE production and upregu-
lates major histocompatibility complex molecules on cell
surfaces [1]. IL-13 shows signi¢cant structural and func-
tional homology with IL-4 [2]. IL-18 is a pleiotropic cyto-
kine and, like IL-12, it plays an important role in the
development of Th1-type cells. Originally, IL-18 was
known as interferon-Q (IFN-Q) inducing factor. IL-18 is
produced by activated blood monocytes and tissue macro-
phages such as Kup¡er cells, and acts primarily as a co-
stimulant for Th1 cells, inducing production of IFN-Q, IL-
2 and GM-CSF, stimulating IL-2R K-chain expression and
Th1 cell proliferation. Additionally, IL-18 enhances allo-
speci¢c CTL activity in vitro, and like IL-12 it augments
cytotoxic NK cell activity and inhibits production of IL-10
(but not of IL-4) [3,4]. Although IL-18 and IL-12 share
the capacity to induce IFN-Q production by activated Th1
cells, their induction pathways seem to be independent,
since neutralizing antibodies to IL-12 do not block IFN-
Q production induced by IL-18 and vice versa [5].
Dengue virus produces either a mild, self-limiting febrile
illness, dengue fever (DF), or a severe, often fatal illness,
dengue hemorrhagic fever (DHF). The characteristic
pathological features of DHF are increased capillary per-
meability, cerebral edema, altered number and functions
of leucocytes, increased hematocrit and thrombocytopenia
[6]. Extensive plasma leakage into various serous cavities
of the body may result in profound shock and death.
Despite extensive studies, the pathogenesis of DHF is still
not fully understood. We have reported a shift from a
Th1-type cytokine response in DF to a Th2-type cytokine
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response in DHF that correlates with increasing severity of
the illness [7]. A similar cytokine response is observed in
dengue virus-infected human peripheral blood leucocyte
cultures [8]. The levels of IL-12 (an inducer of Th1-type
cytokines) were the highest in patients with DF, but this
cytokine could not be detected in the sera of patients with
DHF grades III and IV [9]. While the levels of transform-
ing growth factor L1 (TGF-L1) (an inhibitor of Th1-type
and enhancer of Th2-type cytokines) in patients with
dengue correlated with the severity of the disease and
showed an inverse relationship with IL-12 [10]. This indi-
cated a possible role of Th1-type cytokines in protection
and Th2-type cytokines in pathogenesis of DHF [11]. IL-4
and IL-13 have similar biological activities and are char-
acteristic of cytokines expressed by Th2-type cells. On the
other hand, IL-12 and IL-18 are strong cofactors for de-
velopment of Th1-type cells. To further understand the
role of cytokine-mediated e¡ects, the present study was
undertaken to investigate the possible protective/patholog-
ical role of IL-13 and IL-18 in patients with dengue dis-
ease.
2. Materials and methods
2.1. Patients
For this study, a total of 84 patients with laboratory-
con¢rmed diagnosis of dengue virus infection were se-
lected as described earlier [7,12]. Depending upon the se-
verity of the illness they were classi¢ed as DF, the mildest,
to DHF grades I, II, III or IV, the most severe, according
to the criteria of the World Health Organization [12,13].
As controls, 21 normal age-matched healthy individuals,
without history of any febrile or other illnesses in the
previous 3 months, were included. Among the patients,
24 were classi¢ed as DF, 10 as DHF grade I, 24 as
DHF grade II, and 13 each as DHF grade III and grade
IV. Sera collected from the patients and the controls were
divided into aliquots (to avoid repeated freezing and thaw-
ing) and quickly frozen and stored at 360‡C. For the
cytokine study sera were transported to Kuwait on dry
ice and stored at 370‡C until tested.
2.2. Assay of IL-13 and IL-18
Commercial enzyme-linked immunosorbent assay (ELI-
SA) kits (purchased from RpD Systems, Minneapolis,
MN, USA) were used to measure IL-13 and IL-18 levels
in the sera of patients and controls according to the in-
structions of the manufacturer. All the tests were set up in
duplicate and the data were analyzed by Genesis Windows
Software for microplate-based assays (Labsystems, Fin-
land). By this assay, the minimum detectable concentra-
tions of IL-13 and IL-18 were 1.5 pg ml31 and 12.5 pg
ml31, respectively. The mean value of each cytokine in the
Fig. 1. Levels of IL-13 in patients with dengue. Sera collected from the patients with various grades of the illness were screened for IL-13 concentration
by sandwich ELISA using commercial kits. The mean values (line) of the data (pg ml31) and the percentages of the patients positive for IL-13 (col-
umns) have been presented. The ¢gures in parentheses represent the total number of the cases in each group.
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control sera plus 3 S.D. was used as ‘cut-o¡’ value for
designation of patient sera as positive or negative. The
data were analyzed using Student’s t test. A P value of
less than 0.05 was considered signi¢cant. The ¢ndings are
presented as mean value þ S.D. and percentage of cytokine
positive patients.
3. Results
3.1. Serum levels of IL-13
The mean value of IL-13 in control sera was 4 þ 3 pg
ml31 with a range of 0^8 pg ml31. The ¢ndings presented
Fig. 2. Levels of IL-18 in patients with dengue. Sera collected from the patients with various grades of the illness were screened for IL-18 concentration
by sandwich ELISA using commercial kits. The mean value (line) of the data (pg ml31) and the percentages of the patients positive for IL-18 (columns)
have been presented. The ¢gures in parentheses represent the total number of the cases in each group.
Fig. 3. Amount of IL-13 and IL-18 in patient sera (pg ml31) as a function of the stage of dengue illness. The ¢gures in parentheses represent the total
number of patients in each group.
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in Fig. 1 show that IL-13 was present in the sera of 7^9%
patients with DF, DHF grade I and DHF grade II, while
it was present in 19% patients with DHF grade III and in
44% patients with DHF grade IV. As compared to pa-
tients with DF (mean value of 22 þ 12 pg ml31), signi¢-
cantly higher levels of IL-13 were detected in the sera of
patients with DHF grade III (129 þ 76 pg ml31 ; P6 0.001)
and DHF grade IV (205 þ 103 pg ml31 ; P6 0.001).
The patients were grouped according to the day of the
illness at the time of collection of the sera, as between days
1 and 4, between days 5 and 8 and day 9 onwards. When
the data were analyzed with respect to the days of illness,
it was observed that IL-13 levels were lowest (20 þ 11 pg
ml31) during the ¢rst 4 days of illness, the levels increased
to 180 þ 70 pg ml31 on days 5^8 and peaked to 204 þ 96 pg
ml31 on day 9 onwards (Fig. 3) ; the di¡erence from the
initial period was signi¢cant (P6 0.001).
3.2. Serum levels of IL-18
The mean value of IL-18 in the control sera was 15 þ 4
pg ml31. As compared to the patients with DF (mean
value 76 þ 50 pg ml31), signi¢cantly higher concentrations
of IL-18 were detected in the sera of patients with DHF
grade III (300 þ 110 pg ml31 ; P6 0.001) and grade IV
(366 þ 155 pg ml31 ; P6 0.001) (Fig. 2). Among patients
with DHF, 35%, 40%, 62% and 87% patients with DHF
grade I, grade II, grade III and grade IV, respectively,
were positive, while only 30% of patients with DF were
positive for IL-18 (Fig. 2). One of the DHF grade IV
patients had the highest IL-18 serum concentration of
568 þ 21 pg ml31. The levels of IL-18 during di¡erent
time periods of the illness are presented in Fig. 3. The
data show that serum levels of IL-18 were lowest
(70 þ 45 pg ml31) during 1^4 days of the illness and
reached the highest level (360 þ 148 pg ml31 ; P6 0.001)
on day 9 onwards.
4. Discussion
The ¢ndings of the present study show, for the ¢rst
time, that both the cytokines, IL-13 and IL-18, are asso-
ciated with the severity of the dengue illness and are at
peak levels in patients with DHF grade IV. Our previous
studies on the same group of dengue patients showed a
shift from the predominant Th1-type cytokine response
observed in 66% cases of mild illness (DF) to a Th2-type
response in 71% of the patients with severe DHF grade IV,
which have a high fatality rate [7]. These ¢ndings are sup-
ported by studies carried out in the mouse model [6,14].
During dengue virus infection a unique cytokine, cytotoxic
factor (hCF), is also produced by CD4 T cells, which is
pathogenesis-related and plays a key role in the develop-
ment of DHF [6,11,15]. Recent studies have shown the
presence of hCF autoantibodies in sera of patients with
dengue illness. The high hCF autoantibody levels in pa-
tients with DF are associated with the low levels of hCF.
On the other hand, high hCF levels in patients with DHF
grade IV are associated with low levels of hCF autoanti-
bodies [16]. These ¢ndings support the view that presence
of high levels of hCF autoantibodies, that are neutralizing,
may protect against development of severe DHF [16].
With respect to macrophage cytokines, our previous
studies with DHF patients have shown that the presence
of IL-12 is associated with Th1-type response and its ab-
sence with the Th2-type response [9], while the reverse is
true for TGF-L1 [10]. On the basis of these results, it has
been proposed that dengue virus induces the production of
a cytokine cascade that shifts a Th1-dominant response to
a Th2-biased response resulting in an exacerbation of
dengue disease and possible death of the patients [11].
The ¢ndings of the present study with respect to the high-
est levels of IL-13 (a Th2-type cytokine) in DHF grade IV
patients are in line with the above scheme. Moreover,
Hoshino et al. [17] have recently reported that IL-18 acts
as a potent coinducer of IL-13 in T cells and NK cells.
Whether this is true in patients with severe dengue disease
remains to be investigated.
IL-18 is produced by activated monocytes/macrophages
and acts primarily as a co-stimulant with IL-12, for Th1-
type cells, inducing production of IFN-Q, IL-2 and GM-
CSF, stimulating IL-2R K-chain expression and Th1 cell
proliferation [4]. It has also been shown that IL-18 acts
synergistically with in£uenza A virus-induced IFN-K and
IFN-L to induce IFN-Q production [18]. But the ¢nding of
increased levels of IL-18 in patients with severe dengue
disease, similar to Th2-type cytokines, was unexpected.
However, recent studies show that cytokines may not fol-
low the expected path in di¡erent circumstances. For ex-
ample IL-12 is not essential for the generation of Th1-type
cytokine response in mouse hepatitis virus [19] and lym-
phocytic choriomeningitis virus [20] infections. Marshall et
al. [21] have reported complete restoration of IL-12 pro-
duction by Th2-associated cytokines while other reports
have suggested that IL-18 may act as a strong coinducer
of Th2-type cytokines depending upon the nature of stim-
ulation and the target cell type [22,23].
Macrophages are the primary source of IL-12, TGF-L1
and IL-18 that are important immunoregulatory cytokines
and have multiple roles to play in the pathogenesis of viral
diseases. Macrophages are also the principal cells to rep-
licate dengue virus and present its antigen to immunolog-
ically competent cells (reviewed in [6]). It is possible that a
selective induction to produce IL-18 occurs during dengue
virus infection of macrophages. Similar induction of mac-
rophages to produce IL-18 has been reported through ac-
tivation of caspase-1 in Sendai virus infection [24]. Fur-
ther, on one hand IL-18 has been shown to have an
antiviral e¡ect in a mouse model of vaccinia virus infec-
tion [25] and on the other, IL-18 is associated with the
pathogenesis of autoimmunity [4], arthritis [26], and sepsis
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[27] etc. Therefore, the ¢ndings of increased levels of IL-18
in patients with severe dengue disease, similar to Th2-type
cytokines, although unexpected, may in fact be contribut-
ing to the pathogenesis of severe DHF.
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